The DOI matches its Crossref record; 158 of the 158 references it cites were found in a registry or an index.
PTEN/PTENP1: ‘Regulating the regulator of RTK-dependent PI3K/Akt signalling’, new targets for cancer therapy
Open accessAbstract
Regulation of the PI-3 kinase (PI3K)/Akt signalling pathway is essential for maintaining the integrity of fundamental cellular processes, cell growth, survival, death and metabolism, and dysregulation of this pathway is implicated in the development and progression of cancers. Receptor tyrosine kinases (RTKs) are major upstream regulators of PI3K/Akt signalling. The phosphatase and tensin homologue (PTEN), a well characterised tumour suppressor, is a prime antagonist of PI3K and therefore a negative regulator of this pathway. Loss or inactivation of PTEN, which occurs in many tumour types, leads to overactivation of RTK/PI3K/Akt signalling driving tumourigenesis. Cellular PTEN levels are tightly regulated by a number of transcriptional, post-transcriptional and post-translational regulatory mechanisms. Of particular interest, transcription of the PTEN pseudogene, PTENP1, produces sense and antisense transcripts that exhibit post-transcriptional and transcriptional modulation of PTEN expression respectively. These additional levels of regulatory complexity governing PTEN expression add to the overall intricacies of the regulation of RTK/PI-3 K/Akt signalling. This review will discuss the regulation of oncogenic PI3K signalling by PTEN (the regulator) with a focus on the modulatory effects of the sense and antisense transcripts of PTENP1 on PTEN expression, and will further explore the potential for new therapeutic opportunities in cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Li, N., Miao, Y., Shan, Y., Liu, B., Li, Y., Zhao, L., & Jia, L. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.119 · Cited by 188
RetractedChung, J.-H., Ginn-Pease, M. E., & Eng, C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0124 · Cited by 164
RetractedLewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?
Salmena, L., Poliseno, L., Tay, Y., Kats, L., & Pandolfi, P. P. (2011) · Cell · doi:10.1016/j.cell.2011.07.014 · Cited by 7,262
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330 · cited 1×
“Breast cancer - PTEN mutations in 3% of patients [156, 157]”
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104
Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., & Cohen, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00122-9 · Cited by 2,826
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0497-356 · Cited by 2,741
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
A coding-independent function of gene and pseudogene mRNAs regulates tumour biology
Poliseno, L., Salmena, L., Zhang, J., Carver, B., Haveman, W. J., & Pandolfi, P. P. (2010) · Nature · doi:10.1038/nature09144 · Cited by 2,323
Liaw, D., Marsh, D. J., Li, J., Dahia, P. L. M., Wang, S. I., Zheng, Z., Bose, S., Call, K. M., Tsou, H. C., Peacoke, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-64 · Cited by 2,091
The functions and regulation of the PTEN tumour suppressor
Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926
PI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
Growth factor signaling by receptor tyrosine kinases
Schlessinger, J., & Ullrich, A. (1992) · Neuron · doi:10.1016/0896-6273(92)90177-f · Cited by 1,430
PTEN and the PI3-Kinase Pathway in Cancer
Chalhoub, N., & Baker, S. J. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092311 · Cited by 1,245
The discovery of receptor tyrosine kinases: targets for cancer therapy
Gschwind, A., Fischer, O. M., & Ullrich, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1360 · Cited by 1,227 · cited 5×
“The RTK family consists of a number of subfamilies, including the epidermal growth factor receptors (EGFRs), platelet derived growth factor receptors (PDGFRs), fibroblast growth factor receptors (FGFRs), vascular endothelial growth factor receptors (VEGFRs), insulin growth factor receptors (IGFRs), and hepatocyte grow…”
InfluentialMicroRNA: Function, Detection, and Bioanalysis
Dong, H., Lei, J., Ding, L., Wen, Y., Ju, H., & Zhang, X. (2013) · Chemical Reviews · doi:10.1021/cr300362f · Cited by 1,224
Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN
Tamura, M., Gu, J., Matsumoto, K., Aota, S.-I., Parsons, R., & Yamada, K. M. (1998) · Science · doi:10.1126/science.280.5369.1614 · Cited by 1,215
The lipid phosphatase activity of PTEN is critical for its tumor supressor function
Myers, M. P., Pass, I., Batty, I. H., Van der Kaay, J., Stolarov, J. P., Hemmings, B. A., Wigler, M. H., Downes, C. P., & Tonks, N. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13513 · Cited by 1,168
Reversible Inactivation of the Tumor Suppressor PTEN by H2O2
Lee, S.-R., Yang, K.-S., Kwon, J., Lee, C., Jeong, W., & Rhee, S. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111899200 · Cited by 1,057
An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.
Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054
Tenets of PTEN Tumor Suppression
Salmena, L., Carracedo, A., & Pandolfi, P. P. (2008) · Cell · doi:10.1016/j.cell.2008.04.013 · Cited by 1,034
Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs
Tay, Y., Kats, L., Salmena, L., Weiss, D., Tan, S. M., Ala, U., Karreth, F., Poliseno, L., Provero, P., Di Cunto, F., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.029 · Cited by 1,019
Crystal Structure of the PTEN Tumor Suppressor
Lee, J.-O., Yang, H., Georgescu, M.-M., Di Cristofano, A., Maehama, T., Shi, Y., Dixon, J. E., Pandolfi, P., & Pavletich, N. P. (1999) · Cell · doi:10.1016/s0092-8674(00)81663-3 · Cited by 1,014
PTEN deletion enhances the regenerative ability of adult corticospinal neurons
Liu, K., Lu, Y., Lee, J. K., Samara, R., Willenberg, R., Sears-Kraxberger, I., Tedeschi, A., Park, K. K., Jin, D., Cai, B., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2603 · Cited by 985
Meng, F., Henson, R., Lang, M., Wehbe, H., Maheshwari, S., Mendell, J. T., Jiang, J., Schmittgen, T. D., & Patel, T. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.057 · Cited by 984
Li, D., & Sun, H. (1997) · PubMed · Cited by 866
C2-domains, Structure and Function of a Universal Ca2+-binding Domain
Rizo, J., & Südhof, T. C. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.26.15879 · Cited by 862
Sun, H., Lesche, R., Li, D.-M., Liliental, J., Zhang, H., Gao, J., Gavrilova, N., Mueller, B., Liu, X., & Wu, H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6199 · Cited by 796
PTEN loss in the continuum of common cancers, rare syndromes and mouse models
Hollander, M. C., Blumenthal, G. M., & Dennis, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3037 · Cited by 794
PTEN: One Gene, Many Syndromes
Eng, C. (2003) · Human Mutation · doi:10.1002/humu.10257 · Cited by 787
Butler, M. G., Dasouki, M. J., Zhou, X.-P., Talebizadeh, Z., Brown, M., Takahashi, T. N., Miles, J. H., Wang, C. H., Stratton, R., Pilarski, R., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.024646 · Cited by 778
Phosphorylation of the PTEN Tail Regulates Protein Stability and Function
Vazquez, F., Ramaswamy, S., Nakamura, N., & Sellers, W. R. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.14.5010-5018.2000 · Cited by 774
Ubiquitination regulates PTEN nuclear import and tumor suppression
Trotman, L. C., Wang, X., Alimonti, A., Chen, Z., Teruya-Feldstein, J., Yang, H., Pavletich, N. P., Carver, B. S., Cordon-Cardo, C., Erdjument-Bromage, H., et al. (2007) · Cell · doi:10.1016/j.cell.2006.11.040 · Cited by 748 · cited 4×
“Polyubiquitination of PTEN results in decreased protein stability leading to PTEN degradation by proteasome mediated decay mechanisms [24], whereas monoubiquitination of PTEN on Lys13 and Lys289 promotes the nuclear transport of PTEN [24, 80].”
InfluentialMitochondrial Defects and Oxidative Stress in Alzheimer Disease and Parkinson Disease
Yan, M. H., Wang, X., & Zhu, X. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.11.014 · Cited by 718
PTEN: Life as a Tumor Suppressor
Simpson, L., & Parsons, R. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5130 · Cited by 679
The Tumor Suppressor PTEN Is Phosphorylated by the Protein Kinase CK2 at Its C Terminus
Torres, J., & Pulido, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009134200 · Cited by 629
Subtle variations in Pten dose determine cancer susceptibility
Alimonti, A., Carracedo, A., Clohessy, J. G., Trotman, L. C., Nardella, C., Egia, A., Salmena, L., Sampieri, K., Haveman, W. J., Brogi, E., et al. (2010) · Nature Genetics · doi:10.1038/ng.556 · Cited by 580
Worby, C. A., & Dixon, J. E. (2014) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-082411-113907 · Cited by 535
Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration
Graupera, M., Guillermet-Guibert, J., Foukas, L. C., Phng, L.-K., Cain, R. J., Salpekar, A., Pearce, W., Meek, S., Millan, J., Cutillas, P. R., et al. (2008) · Nature · doi:10.1038/nature06892 · Cited by 520
Deregulation of sphingolipid metabolism in Alzheimer’s disease
He, X., Huang, Y., Li, B., Gong, C.-X., & Schuchman, E. H. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.05.010 · Cited by 516
Zhang, S., Huang, W.-C., Li, P., Guo, H., Poh, S.-B., Brady, S. W., Xiong, Y., Tseng, L.-M., Li, S.-H., Ding, Z., et al. (2011) · Nature Medicine · doi:10.1038/nm.2309 · Cited by 515
Freeman, D. J., Li, A. G., Wei, G., Li, H.-H., Kertesz, N., Lesche, R., Whale, A. D., Martinez-Diaz, H., Rozengurt, N., Cardiff, R. D., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00021-7 · Cited by 515
Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
LoRusso, P. M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0018 · Cited by 470
Pseudogenes: Pseudo-functional or key regulators in health and disease?
Pink, R. C., Wicks, K., Caley, D. P., Punch, E. K., Jacobs, L., & Francisco Carter, D. R. (2011) · RNA · doi:10.1261/rna.2658311 · Cited by 465
PTEN: Multiple Functions in Human Malignant Tumors
Milella, M., Falcone, I., Conciatori, F., Cesta Incani, U., Del Curatolo, A., Inzerilli, N., Nuzzo, C. M. A., Vaccaro, V., Vari, S., Cognetti, F., et al. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00024 · Cited by 463
A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells
Johnsson, P., Ackley, A., Vidarsdottir, L., Lui, W.-O., Corcoran, M., Grandér, D., & Morris, K. V. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2516 · Cited by 436
Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain
Furnari, F. B., Lin, H., Huang, H.-J. S., & Cavenee, W. K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12479 · Cited by 434
The PTEN, Mdm2, p53 tumor suppressor–oncoprotein network
Mayo, L. D., & Donner, D. B. (2002) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(02)02166-7 · Cited by 410
Poliseno, L., Salmena, L., Riccardi, L., Fornari, A., Song, M. S., Hobbs, R. M., Sportoletti, P., Varmeh, S., Egia, A., Fedele, G., et al. (2010) · Science Signaling · doi:10.1126/scisignal.2000594 · Cited by 410 · cited 2×
“regulatory cycle is supported by experiments in which knockdown of PTENP1 results in decreased PTEN mRNA and protein levels [33].”
Mighell, A. J., Smith, N. R., Robinson, P. A., & Markham, A. F. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01199-6 · Cited by 407
Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress
Bassi, C., Ho, J., Srikumar, T., Dowling, R. J. O., Gorrini, C., Miller, S. J., Mak, T. W., Neel, B. G., Raught, B., & Stambolic, V. (2013) · Science · doi:10.1126/science.1236188 · Cited by 403
Systemic elevation of PTEN induces a tumor-suppressive metabolic state
Garcia-Cao, I., Song, M. S., Hobbs, R. M., Laurent, G., Giorgi, C., de Boer, V. C. J., Anastasiou, D., Ito, K., Sasaki, A. T., Rameh, L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.030 · Cited by 377
Patel, L., Pass, I., Coxon, P., Downes, C. P., Smith, S. A., & Macphee, C. H. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00225-1 · Cited by 365
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
NITULESCU, G. M., MARGINA, D., JUZENAS, P., PENG, Q., OLARU, O. T., SALOUSTROS, E., FENGA, C., SPANDIDOS, D. A., LIBRA, M., & TSATSAKIS, A. M. (2016) · International Journal of Oncology · doi:10.3892/ijo.2015.3306 · Cited by 364
Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity
Cao, J., Schulte, J., Knight, A., Leslie, N. R., Zagozdzon, A., Bronson, R., Manevich, Y., Beeson, C., & Neumann, C. A. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.101 · Cited by 344
Akt-regulated pathways in prostate cancer
Majumder, P. K., & Sellers, W. R. (2005) · Oncogene · doi:10.1038/sj.onc.1209096 · Cited by 344
PTEN: from pathology to biology
Sulis, M. (2003) · Trends in Cell Biology · doi:10.1016/s0962-8924(03)00175-2 · Cited by 344
Receptor Tyrosine Kinases: Legacy of the First Two Decades
Schlessinger, J. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008912 · Cited by 340
Yao, Y., Ma, J., Xue, Y., Wang, P., Li, Z., Liu, J., Chen, L., Xi, Z., Teng, H., Wang, Z., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.12.051 · Cited by 338
Membrane-binding and activation mechanism of PTEN
Das, S., Dixon, J. E., & Cho, W. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932835100 · Cited by 335
The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region
Georgescu, M.-M., Kirsch, K. H., Akagi, T., Shishido, T., & Hanafusa, H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10182 · Cited by 317
PTEN function: the long and the short of it
Hopkins, B. D., Hodakoski, C., Barrows, D., Mense, S. M., & Parsons, R. E. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.02.006 · Cited by 309 · cited 1×
“null prostate cancer cells (PC-3) [138] induced apoptosis and regression of PTEN-null xenograft tumors in mice [139].”
Planchon, S. M., Waite, K. A., & Eng, C. (2008) · Journal of Cell Science · doi:10.1242/jcs.022459 · Cited by 293
Cancer-Associated PTEN Mutants Act in a Dominant-Negative Manner to Suppress PTEN Protein Function
Papa, A., Wan, L., Bonora, M., Salmena, L., Song, M. S., Hobbs, R. M., Lunardi, A., Webster, K., Ng, C., Newton, R. H., et al. (2014) · Cell · doi:10.1016/j.cell.2014.03.027 · Cited by 276
RNA–RNA interactions in gene regulation: the coding and noncoding players
Guil, S., & Esteller, M. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.03.001 · Cited by 264
Al-Khouri, A. M., Ma, Y., Togo, S. H., Williams, S., & Mustelin, T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503045200 · Cited by 252
Fluorescence microphotolysis to measure nucleocytoplasmic transport and intracellular mobility
Peters, R. (1986) · Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes · doi:10.1016/0304-4157(86)90003-1 · Cited by 246
Marsit, C. J., Zheng, S., Aldape, K., Hinds, P. W., Nelson, H. H., Wiencke, J. K., & Kelsey, K. T. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.05.006 · Cited by 243
PTEN Mutations as a Cause of Constitutive Insulin Sensitivity and Obesity
Pal, A., Barber, T. M., Van de Bunt, M., Rudge, S. A., Zhang, Q., Lachlan, K. L., Cooper, N. S., Linden, H., Levy, J. C., Wakelam, M. J. O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113966 · Cited by 234
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design
Massacesi, C., Di Tomaso, E., Urban, P., Germa, C., Quadt, C., Trandafir, L., Aimone, P., Fretault, N., Dharan, B., Tavorath, R., et al. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s89967 · Cited by 229
Pseudogenes regulate parental gene expression via ce RNA network
An, Y., Furber, K. L., & Ji, S. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12952 · Cited by 227
Okumura, K., Mendoza, M., Bachoo, R. M., DePinho, R. A., Cavenee, W. K., & Furnari, F. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605391200 · Cited by 224
Kinase inhibitors and monoclonal antibodies in oncology: clinical implications
Gharwan, H., & Groninger, H. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.213 · Cited by 224
Beyond BRCA: New hereditary breast cancer susceptibility genes
Economopoulou, P., Dimitriadis, G., & Psyrri, A. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.10.008 · Cited by 223
Yang, Q., Modi, P., Newcomb, T., Quéva, C., & Gandhi, V. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2034 · Cited by 222
Chen, C.-L., Tseng, Y.-W., Wu, J.-C., Chen, G.-Y., Lin, K.-C., Hwang, S.-M., & Hu, Y.-C. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.12.023 · Cited by 214
PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis
Fang, J., Ding, M., Yang, L., Liu, L.-Z., & Jiang, B.-H. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.07.025 · Cited by 205
Singh, P., Alex, J. M., & Bast, F. (2014) · Medical Oncology · doi:10.1007/s12032-013-0805-3 · Cited by 203
Huang, J., Yan, J., Zhang, J., Zhu, S., Wang, Y., Shi, T., Zhu, C., Chen, C., Liu, X., Cheng, J., et al. (2012) · Nature Communications · doi:10.1038/ncomms1919 · Cited by 200
Yu, G., Yao, W., Gumireddy, K., Li, A., Wang, J., Xiao, W., Chen, K., Xiao, H., Li, H., Tang, K., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0245 · Cited by 197
Oct4 pseudogenes are transcribed in cancers
Suo, G., Han, J., Wang, X., Zhang, J., Zhao, Y., Zhao, Y., & Dai, J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.157 · Cited by 194
Broek, R. V., Mohan, S., Eytan, D. F., Chen, Z., & Waes, C. V. (2013) · Oral Diseases · doi:10.1111/odi.12206 · Cited by 178
Pathology and genetics of hereditary colorectal cancer
Ma, H., Brosens, L. A. A., Offerhaus, G. J. A., Giardiello, F. M., de Leng, W. W. J., & Montgomery, E. A. (2018) · Pathology · doi:10.1016/j.pathol.2017.09.004 · Cited by 175
Regulation of DNA Pairing in Homologous Recombination
Daley, J. M., Gaines, W. A., Kwon, Y., & Sung, P. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a017954 · Cited by 172
Shen, Y. H., Zhang, L., Gan, Y., Wang, X., Wang, J., LeMaire, S. A., Coselli, J. S., & Wang, X. L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511105200 · Cited by 170
Ming, M., & He, Y. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.003 · Cited by 168
PTEN Acetylation Modulates Its Interaction with PDZ Domain
Ikenoue, T., Inoki, K., Zhao, B., & Guan, K.-L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1107 · Cited by 168
The role of microRNAs in colorectal cancer
Liu, M., & Chen, H. (2010) · Journal of Genetics and Genomics · doi:10.1016/s1673-8527(09)60053-9 · Cited by 166
Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy
Zhao, W., Qiu, Y., & Kong, D. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.07.006 · Cited by 166
Herman, G. E., Butter, E., Enrile, B., Pastore, M., Prior, T. W., & Sommer, A. (2007) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.31619 · Cited by 160
PTEN recruitment controls synaptic and cognitive function in Alzheimer's models
Knafo, S., Sánchez‐Puelles, C., Palomer, E., Delgado, I., Draffin, J. E., Mingo, J., Wahle, T., Kaleka, K. S., Mou, L., Pereda-Pérez, I., et al. (2016) · Nature Neuroscience · doi:10.1038/nn.4225 · Cited by 160
PTEN mutations are common in sporadic microsatellite stable colorectal cancer
Nassif, N. T., Lobo, G. P., Wu, X., Henderson, C. J., Morrison, C. D., Eng, C., Jalaludin, B. B., & Segelov, E. (2004) · Oncogene · doi:10.1038/sj.onc.1207059 · Cited by 158
Self-citationThe role of microRNAs in colorectal cancer
Mohammadi, A., Mansoori, B., & Baradaran, B. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.09.099 · Cited by 157
Neuropathology and Molecular Genetics of Neurofibromatosis 2 and Related Tumors
Louis, D. N., Ramesh, V., & Gusella, J. F. (1995) · Brain Pathology · doi:10.1111/j.1750-3639.1995.tb00590.x · Cited by 156
LncRNAs: From Basic Research to Medical Application
Wu, T., & Du, Y. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.16968 · Cited by 154
Bonofiglio, D., Gabriele, S., Aquila, S., Catalano, S., Gentile, M., Middea, E., Giordano, F., & Andò, S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2453 · Cited by 152
Gil, A., Andrés‐Pons, A., Fernández, E., Valiente, M., Torres, J., Cervera, J., & Pulido, R. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-05-0380 · Cited by 146
CHIEFARI, E. D., Iiritano, S., Paonessa, F., Pera, I. L., Arcidiacono, B., Filocamo, M., FOTI, D. P., Liebhaber, S. A., & Brunetti, A. (2010) · Nature Communications · doi:10.1038/ncomms1040 · Cited by 146
PTEN ceRNA networks in human cancer
Poliseno, L., & Pandolfi, P. P. (2015) · Methods · doi:10.1016/j.ymeth.2015.01.013 · Cited by 141
Targeting PI3K Signaling as a Therapeutic Approach for Colorectal Cancer
Zhang, J., Roberts, T. M., & Shivdasani, R. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.05.010 · Cited by 130
PTEN is a protein tyrosine phosphatase for IRS1
Shi, Y., Wang, J., Chandarlapaty, S., Cross, J. R., Thompson, C. B., Rosen, N. X., & Jiang, X. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2828 · Cited by 128
PI3K isoform-selective inhibitors: next-generation targeted cancer therapies
Wang, X., Ding, J., & Meng, L. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.71 · Cited by 128
Germline mutation of the tumour suppressor PTEN in Proteus syndrome
Smith, J. M., Kirk, E. P. E., Theodosopoulos, G., Marshall, G. M., Walker, J., Rogers, M., Field, M., Brereton, J. J., & Marsh, D. J. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.12.937 · Cited by 124
Functional analysis of the protein phosphatase activity of PTEN
Zhang, X. C., Piccini, A., Myers, M. P., Aelst, L. V., & Tonks, N. K. (2012) · Biochemical Journal · doi:10.1042/bj20120098 · Cited by 117
Tibarewal, P., Zilidis, G., Spinelli, L., Schurch, N., Maccario, H., Gray, A., Perera, N. M., Davidson, L., Barton, G. J., & Leslie, N. R. (2012) · Science Signaling · doi:10.1126/scisignal.2002138 · Cited by 117
PTEN enters the nucleus by diffusion
Liu, F., Wagner, S., Campbell, R. B., Nickerson, J. A., Schiffer, C. A., & Ross, A. H. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20525 · Cited by 114
Post-translational regulation of PTEN
Wang, X., & Jiang, X. (2008) · Oncogene · doi:10.1038/onc.2008.242 · Cited by 113
Deletion of PTENP1 Pseudogene in Human Melanoma
Poliseno, L., Haimovic, A., Christos, P. J., de Miera, E. C. V. Y. S., Shapiro, R. L., Pavlick, A. C., Berman, R. S., Darvishian, F., & Osman, I. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.232 · Cited by 109
Breast cancer risk and clinical implications for germline PTEN mutation carriers
Ngeow, J. Y. Y., Sesock, K., & Eng, C. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3665-z · Cited by 108
The tumor suppressor PTEN interacts with p53 in hereditary cancer
NAKANISHI, A., Kitagishi, Y., Ogura, Y., & Matsuda, S. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2377 · Cited by 107
Denning, G., Jean-Joseph, B., Prince, C. Z., Durden, D. L., & Vogt, P. K. (2007) · Oncogene · doi:10.1038/sj.onc.1210175 · Cited by 102
Chae, H.-D., & Broxmeyer, H. E. (2010) · Stem Cells and Development · doi:10.1089/scd.2010.0465 · Cited by 101
Yang, J.-M., Schiapparelli, P. V., Nguyen, H.-N., Igarashi, A., Zhang, Q., Abbadi, S., Amzel, L. M., Sesaki, H., Quiñones‐Hinojosa, A., & Iijima, M. (2017) · Oncogene · doi:10.1038/onc.2016.493 · Cited by 101
A highly conserved processed PTEN pseudogene is located on chromosome band 9p21
Dahia, P. L., FitzGerald, M. G., Zhang, X., Marsh, D. J., Zheng, Z., Pietsch, T., von Deimling, A., Haluska, F. G., Haber, D. A., & Eng, C. (1998) · Oncogene · doi:10.1038/sj.onc.1201762 · Cited by 99
The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer
Carden, C. P., Stewart, A., Thavasu, P., Kipps, E., Pope, L., Crespo, M., Miranda, S., Attard, G., Garrett, M. D., Clarke, P. A., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0996 · Cited by 96
PTEN, Insulin Resistance and Cancer
Li, A., Qiu, M., Zhou, H., Wang, T., & Guo, W. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612823666170704124611 · Cited by 94
Balancing Proliferation and Connectivity in PTEN-associated Autism Spectrum Disorder
Tilot, A. K., Frazier, T. W., & Eng, C. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0356-8 · Cited by 93
Pseudogenes: Pseudo or Real Functional Elements?
Li, W., Yang, W., & Wang, X. (2013) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2013.03.003 · Cited by 91
The deubiquitylase Ataxin-3 restricts PTEN transcription in lung cancer cells
Sacco, J. J., Yau, T. Y., Darling, S., Patel, V., Liu, H., Urbé, S., Clague, M. J., & Coulson, J. M. (2013) · Oncogene · doi:10.1038/onc.2013.512 · Cited by 86
Prostate cancer heterogeneity: Discovering novel molecular targets for therapy
Ciccarese, C., Massari, F., Iacovelli, R., Fiorentino, M., Montironi, R., Nunno, V. D., Giunchi, F., Brunelli, M., & Tortora, G. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.02.001 · Cited by 86
Minaguchi, T., Waite, K. A., & Eng, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2240 · Cited by 85
Gao, L., Ren, W., Zhang, L., Li, S., Kong, X., Zhang, H., Dong, J., Cai, G., Jin, C., Zheng, D., et al. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22594 · Cited by 85
Transcriptional analysis of the PTEN/MMAC1 pseudogene, ΨPTEN
Fujii, G. H., Morimoto, A. M., Berson, A. E., & Bolen, J. B. (1999) · Oncogene · doi:10.1038/sj.onc.1202492 · Cited by 84
Assessing the genomic evidence for conserved transcribed pseudogenes under selection
Khachane, A. N., & Harrison, P. M. (2009) · BMC Genomics · doi:10.1186/1471-2164-10-435 · Cited by 80
The Therapeutic Potential of PTEN Modulation: Targeting Strategies from Gene to Protein
McLoughlin, N. M., Mueller, C., & Grossmann, T. N. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.10.009 · Cited by 80
Molecular Evolution of the Cecropin Multigene Family in Drosophila: Functional Genes vs. Pseudogenes
Ramos-Onsins, S. E., & Aguadé, M. (1998) · Genetics · doi:10.1093/genetics/150.1.157 · Cited by 78
Accumulation of tumor-suppressor PTEN in Alzheimer neurofibrillary tangles
Sonoda, Y., Mukai, H., Matsuo, K., Takahashi, M., Ono, Y., Maeda, K., Akiyama, H., & Kawamata, T. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2009.12.078 · Cited by 74
Regulation of the tumor suppressor PTEN by SUMO
González, J., Campagna, M., Ortega-Molina, A., Marcos-Villar, L., de la Cruz-Herrera, C. F., González, D., Gallego, P. P. F., Lopitz‐Otsoa, F., Estéban, M., Rodríguez, M. S., et al. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.135 · Cited by 74
PTEN modulators: a patent review
Boosani, C. S., & Agrawal, D. K. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.768985 · Cited by 74
Inducible and cardiac specific PTEN inactivation protects ischemia/reperfusion injury
Ruan, H., Li, J., Ren, S. V., Gao, J., Li, G., Kim, R., Wu, H., & Wang, Y. (2008) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2008.10.021 · Cited by 73
Carico, C., Nuño, M., Mukherjee, D. R., Elramsisy, A., Dantis, J., Hu, J. L., Rudnick, J. D., Yu, J. S., Black, K. L., Bannykh, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033684 · Cited by 71
Tanaka, M., & Grossman, H. B. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302056 · Cited by 70
Zheng, L., Zhou, K., Liu, S., Zhang, D., Wang, Z., Chen, Z., Yang, J., & Qu, L. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx972 · Cited by 68
Wang, X., Shi, Y., Wang, J., Huang, G., & Jiang, X. (2008) · Biochemical Journal · doi:10.1042/bj20080674 · Cited by 67
Receptor Tyrosine Kinases: Role in Cancer Progression
Sangwan, V., & Park, M. (2006) · Current Oncology · doi:10.3390/curroncol13050019 · Cited by 56
Oncogenic Activation of MAP Kinase by BRAF Pseudogene in Thyroid Tumors
Zou, M., Baitei, E. Y., Alzahrani, A. S., Al-Mohanna, F. A., Farid, N. R., Meyer, B. F., & Shi, Y. (2009) · Neoplasia · doi:10.1593/neo.81044 · Cited by 55
Posttranscriptional Regulation of PTEN Dosage by Noncoding RNAs
He, L. (2010) · Science Signaling · doi:10.1126/scisignal.3146pe39 · Cited by 52
Phelps, M. A., Coss, C. C., Wang, H., Cook, M. S., & Reproducibility Project: Cancer Biology (2016) · eLife · doi:10.7554/elife.12470 · Cited by 51
Liu, J., Xing, Y., Xu, L., Chen, W., Cao, W., & Zhang, C. (2017) · Scientific Reports · doi:10.1038/srep41179 · Cited by 50
Pseudogene-expressed RNAs: a new frontier in cancers
Shi, X., Nie, F., Wang, Z., & Sun, M. (2015) · Tumor Biology · doi:10.1007/s13277-015-4482-z · Cited by 49
McCarrey, J. R., & Riggs, A. D. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.3.679 · Cited by 48
Abounader, R. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.9.2.235 · Cited by 48
Uygur, B., Abramo, K., Leikina, E., Vary, C., Liaw, L., & Wu, W.-S. (2015) · The Prostate · doi:10.1002/pros.22974 · Cited by 45
Ding, L., Chen, D., Liu, P., Pan, Y., Zhong, J., Regan, K. M., Wang, L., Yu, C., Rizzardi, A. E., Liang Cheng, C., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1659 · Cited by 44
Ioffe, Y., Chiappinelli, K. B., Mutch, D. G., Zighelboim, I., & Goodfellow, P. J. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.10.011 · Cited by 42
PTEN‐mediated pathways and their association with treatment‐resistant prostate cancer
Uzoh, C. C., Perks, C. M., Bahl, A. K., Holly, J. M. P., Sugiono, M., & Persad, R. A. (2009) · British Journal of Urology · doi:10.1111/j.1464-410x.2009.08411.x · Cited by 40
Intracellular delivery of the PTEN protein using cationic lipidoids for cancer therapy
Altınoglu, S., Wang, M., Li, K. Q., Li, Y., & Xu, Q. (2016) · Biomaterials Science · doi:10.1039/c6bm00580b · Cited by 40
Characterization of cryptic splicing in germline PTEN intronic variants in Cowden syndrome
Chen, H. J., Romigh, T., Sesock, K., & Eng, C. (2017) · Human Mutation · doi:10.1002/humu.23288 · Cited by 39
Hägerstrand, D., Lindh, M. B., Peña, C., García-Echeverría, C., Nistér, M., Hofmann, F., & Östman, A. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq029 · Cited by 38
Gong, T., Zheng, S., Huang, S. H., Fu, S., Zhang, X., Pan, S., Yang, T., Sun, Y., Wang, Y., Hui, B., et al. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22705 · Cited by 38
Molecular Evolution of PTEN Pseudogenes in Mammals
Tang, J., Ning, R., Zeng, B., & Li, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167851 · Cited by 37
Mester, J. L., Moore, R. A., & Eng, C. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0174 · Cited by 29
Epigenetic regulation of RTK signaling
Spangle, J. M., & Roberts, T. M. (2017) · Journal of Molecular Medicine · doi:10.1007/s00109-017-1546-0 · Cited by 27
A common variation of the PTEN gene is associated with peripheral insulin resistance
Grinder-Hansen, L., Ribel‐Madsen, R., Wojtaszewski, J. F. P., Poulsen, P., Grunnet, L. G., & Vaag, A. A. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.03.003 · Cited by 19
Bassi, C., & Stambolic, V. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.127 · Cited by 14
Kitagishi, Y. (2014) · International Neuropsychiatric Disease Journal · doi:10.9734/indj/2014/5691 · Cited by 6
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,520
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 784
Regulation of PD-L1 expression in the tumor microenvironment
Yi, M., Niu, M., Xu, L., Luo, S., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01027-5 · Cited by 681
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Zhang, H., Dai, Z., Wu, W., Wang, Z., Zhang, N., Zhang, L., Zeng, W.-J., Liu, Z., & Cheng, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01987-7 · Cited by 535
Metadata
- Authors
- Haddadi, N., Lin, Y., Travis, G., Simpson, A. M., Nassif, N. T., & McGowan, E. M.
- Venue
- Molecular Cancer
- Published
- 2018-02-19
- Volume
- 17
- Issue
- 1
- Pages
- 37-37
- ISSN
- 1476-4598 (ISSN-L)
- OpenAlex
- W2795174081
- Cited by
- 312
- References
- 158
- FWCI
- 8.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.